Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) plus cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)

Autor: Galsky, M. D. Guan, X. Banchereau, R. Wang, L. Zhu, J. and Yu, H. Rishipathak, D. Hajaj, E. Herbst, R. H. and Davis, I. D. Grande, E. Bamias, A. De Santis, M. Arranz, J. A. Kikuchi, E. Zhang, J. Lee, C. Shen, X. Black, P. C. Mariathasan, S.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ac467de88aa534b8bf02cfac81936953
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3031612

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)

Autor: Grande Pulido, E., Galsky, M.D., Van Elzen, R., Banchereau, R., Peterson, M., Sedano, C., Koeppen, H., Li, H., Bamias, A., Arranz Arija, J.A., Kikuchi, E., De Santis, M., Davis, I.D., Mellman, I., Oh, S., Williams, P., Bernhard, S., Lee, C.P., Kockx, M., Mariathasan, S.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1329-S1329

Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

Autor: Arostegui JI, Anton-Lopez J, Calvo I, Robles A, Iglesias-Jimenez E, López-Montesinos B, Banchereau R, Hong S, Joubert Y, Junge G, Pascual V, Yagüe J

Publikováno v: ARTHRITIS & RHEUMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu

OBJECTIVE: To evaluate the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome (HIDS). METHODS: This was a 3-part open-label study with an initial 6-month treatment period in which patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::076cd02495193257e0d059e81f029caf
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6407

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.